BioPro Pharmaceutical, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BioPro Pharmaceutical, Inc.
The worldwide joint-replacement implants market is expected to hit $20bn by 2022, according to a new report from Meddevicetracker. The growth is driven by the rising number of elderly patients, whose natural joints have been damaged by arthritis, and the rising prevalence of chronic diseases, such as obesity and diabetes, and sport-related injuries. But a look at the market and the three largest segments – shoulder, knee and hip replacements – show that new technological advancements and improved surgical techniques are increasingly making joint replacement surgeries an option for younger people as well. Here's an overview and key insights from two orthopedic surgeons on the current market and key growth drivers and limiters.
Ranbaxy Laboratorieshas signed an exclusive licensing agreement with BioPro Pharmaceutical of the US to promote and market Gliadel Wafer (polifeprosan 20 with carmustine implant) in India. The US FDA-approved product is used for the treatment of newly diagnosed high-grade malignant gliomas and recurrent glioblastoma multiforme. Ranbaxy has received import permission for Gliadel Wafer in India. The product is manufactured by MGI Pharma and BioPro retains the marketing rights in some Asian territories including China, Hong Kong, Taiwan, Korea, Singapore, Indonesia, the Philippines, Malaysia, Thailand and India. Gliadel is approved in several countries including many in Europe, Australia, Canada, South Africa, Israel and Korea. Unofficial estimates peg the prevalence of CNS tumours in India at two to five new cases per 100,000 per year.
- Specialty Pharmaceuticals